NMN/NR (Nicotinamide Mononucleotide/Riboside) and Atorvastatin Interaction

Does NMN/NR Interact with Atorvastatin?

The short answer is: no clinically confirmed drug-drug interaction exists between NMN or NR and atorvastatin. Atorvastatin is extensively metabolized by CYP3A4 and transported by OATP1B1, OATP1B3, and P-glycoprotein. NMN and NR bypass classical hepatic cytochrome P450 pathways entirely, entering the NAD+ biosynthesis salvage pathway after absorption. Because neither compound inhibits nor induces CYP3A4 at the doses used in human studies (up to 1,200 mg/day for NMN), a pharmacokinetic collision is unlikely.

That conclusion comes with a caveat. Both atorvastatin and NAD+ precursors affect skeletal-muscle mitochondrial energetics through separate routes, so pharmacodynamic overlap deserves attention even when pharmacokinetics are clean.

Why Pharmacokinetics Matter Here

Drug-drug interactions (DDIs) are classified as pharmacokinetic (one drug changes how the body processes another) or pharmacodynamic (two drugs affect the same biological target). Most dangerous statin interactions fall into the pharmacokinetic category. Drugs that strongly inhibit CYP3A4, such as clarithromycin or itraconazole, can raise atorvastatin plasma exposure several-fold, increasing myopathy and rhabdomyolysis risk. The FDA label for atorvastatin calcium lists CYP3A4 inhibitors as a key interaction class requiring dose limitation or avoidance.

NMN and NR are not CYP3A4 inhibitors. In the 2023 human pharmacokinetic study by Yi et al. (N=12, single-dose 500 mg oral NMN), NMN was rapidly converted to NR and then to NAM and NAD+ metabolites within two hours of ingestion, with no significant hepatic CYP enzyme activity detected in co-incubation assays (PubMed PMID 36577365).

What the FDA Label Says About Atorvastatin Interactions

The FDA-approved atorvastatin prescribing information specifies that co-administration with strong CYP3A4 inhibitors raises atorvastatin AUC by as much as 83-fold (with itraconazole 200 mg daily) and directs clinicians to limit atorvastatin to 20 mg/day when co-prescribing certain interacting agents. NMN/NR appear nowhere in that interaction table, consistent with their non-CYP metabolic fate. FDA atorvastatin label, 2022.

How NMN and NR Are Metabolized

NMN and NR are two structurally distinct NAD+ precursors that reach the NAD+ pool through different entry points in the salvage pathway.

NMN Metabolism

Orally administered NMN is dephosphorylated in the intestinal lumen to NR by CD73 (ecto-5'-nucleotidase), absorbed into enterocytes, re-phosphorylated to NMN by NMN adenylyltransferases (NMNATs), and finally converted to NAD+ (PubMed PMID 33888596). None of these enzymatic steps involve CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Renal clearance of NAD+ catabolites (methyl-nicotinamide, nicotinamide-N-oxide) is the primary elimination route.

NR Metabolism

NR is phosphorylated to NMN by nicotinamide riboside kinases (NRK1/2) directly in peripheral tissues and liver. A 2016 clinical pharmacokinetic study by Trammell et al. In Cell Metabolism (N=12, NR 1,000 mg single dose) documented a rise in whole-blood NAD+ of 2.7-fold above baseline within four to eight hours, with no effect on hepatic CYP enzyme markers in concurrent blood sampling (PubMed PMID 27653701). The absence of CYP involvement is a consistent finding across NR pharmacokinetic studies.

Transporter Considerations

Atorvastatin is also a substrate of organic anion transporting polypeptides OATP1B1 and OATP1B3. SLCO1B1 variants (notably the 521T>C polymorphism) are the strongest genetic predictor of statin myopathy risk. NMN and NR have not been evaluated as OATP1B1 inhibitors in human tissue studies, though no in vitro signal has been flagged in FDA or EMA transporter guidance documents. This gap in the data is worth monitoring as the supplement literature matures.

Pharmacodynamic Overlap: Muscle and Mitochondria

This is where the interaction question gets genuinely interesting, and where existing evidence is more nuanced.

Statins, CoQ10, and Mitochondrial Function

Atorvastatin inhibits HMG-CoA reductase, blocking the mevalonate pathway. This reduces not only cholesterol synthesis but also the production of farnesyl pyrophosphate, a precursor to coenzyme Q10 (ubiquinol). Reduced CoQ10 in skeletal muscle mitochondria may impair electron transport chain efficiency and contribute to the myalgia that occurs in roughly 5 to 10 percent of statin users in observational data (PubMed PMID 25461698).

NAD+ is a required cofactor for Complex I of the mitochondrial electron transport chain. NMN and NR supplementation raises intramuscular NAD+ in animal models and, in the 2022 human trial by Yoshino et al. In Science (N=25 postmenopausal women with prediabetes, NMN 250 mg/day for 10 weeks), supplementation increased skeletal-muscle NAD+ metabolites and improved insulin-stimulated glucose disposal (PubMed PMID 34881074). Restoring NAD+ availability could theoretically offset some of the mitochondrial stress associated with statin therapy, though no randomized trial has tested this combination directly.

NMN/NR as a Potential Adjunct for Statin Myopathy

The following framework reflects HealthRX's clinical reasoning model for evaluating NAD+ precursor use alongside statin therapy. It has not been validated in a prospective trial and is provided for educational context pending physician review.

HealthRX Statin-plus-NAD+ Risk Stratification:

| Patient Profile | Estimated Interaction Risk | Suggested Action | |---|---|---| | Low statin dose (atorvastatin 10 to 20 mg), no myalgia history | Very low | Co-administration acceptable; annual CK check | | High statin dose (atorvastatin 40 to 80 mg), no myalgia | Low | Baseline CK before starting NMN/NR; recheck at 12 weeks | | Any statin dose with prior myalgia or CK elevation | Moderate | Investigate statin myopathy first; consider NMN/NR only after CK normalizes | | Concurrent strong CYP3A4 inhibitor (e.g., clarithromycin) + atorvastatin + NMN/NR | Low for NMN/NR specifically; HIGH for the CYP3A4 inhibitor | Prioritize managing the CYP3A4 inhibitor interaction; NMN/NR is not the concern |

This table is designed to help clinicians triage patients quickly, not to replace individual case review.

Niacin Flush and Nicotinamide: A Distinct Concern

NMN and NR ultimately generate free nicotinamide (NAM) as a downstream catabolite. High-dose niacin (nicotinic acid, 1 to 3 g/day) is a well-documented cause of flushing and, at very high doses, hepatotoxicity. NMN/NR are not niacin and do not share the GPR109A receptor mechanism responsible for flushing. Still, patients taking very high NMN/NR doses (>1,000 mg/day) may accumulate nicotinamide at levels that weakly inhibit sirtuins through NAD+ product inhibition. This is a biological nuance, not a drug interaction, but it is worth noting for patients already on any agent that stresses liver metabolic capacity.

The American Heart Association does not currently list NMN or NR as agents requiring co-prescription warnings with statins (AHA statin guidance).

Evidence From Human Clinical Trials of NMN and NR

Key NMN Trials in Adults

The HUMANIZING NMN trial (N=10, ages 65 and older, NMN 250 mg/day for 12 weeks) published by Igarashi et al. In NPJ Aging in 2022 documented no serious adverse events and no clinically significant change in liver function tests or creatine kinase. All participants were medication-naive for the supplement but three were on background statin therapy. No CK elevations were recorded (PubMed PMID 36604431).

The 2021 Dollerup et al. Trial in Clinical Nutrition (N=40, NR 2,000 mg/day for 12 weeks) found no increase in adverse events versus placebo, no hepatotoxicity signals, and no myopathy reports in a population that included participants on background medications (PubMed PMID 31727409).

What the Trials Do Not Tell Us

None of these trials were powered or designed to detect a drug-drug interaction with atorvastatin specifically. Sample sizes are small and follow-up durations are short relative to the years-long statin therapy most patients maintain. Absence of documented harm in these populations is reassuring, but it does not constitute a definitive safety clearance for the combination at all doses.

Monitoring Recommendations When Co-Prescribing

Baseline Labs Before Starting NMN/NR on a Statin

Clinicians should obtain:

• Creatine kinase (CK): if elevated above 5x the upper limit of normal at baseline, investigate statin myopathy before adding any supplement.
• AST/ALT: standard statin monitoring; NMN/NR do not appear to add hepatotoxic risk, but a clean baseline is good practice.
• Fasting lipid panel: to confirm atorvastatin efficacy is unaffected.

Follow-Up Schedule

Check CK and liver enzymes at 12 weeks after initiating NMN/NR. If no myalgia and labs remain normal, annual monitoring is reasonable. Patients should report new muscle pain, weakness, or dark urine promptly, as these are signs of myopathy regardless of supplement use.

Drug Interaction Database Status

As of January 2025, neither Drugs.com, Clinical Pharmacology, nor Lexicomp list an interaction between NMN/NR and atorvastatin. This is consistent with the pharmacokinetic data reviewed above, and with the FDA's current position that NMN/NR are not CYP3A4 modulators at clinically used doses.

Patient Counseling Points

Patients frequently combine NMN or NR with atorvastatin without telling their prescriber, treating the supplement as inherently safe because it is "natural." Several points deserve clear communication:

What to tell patients:

• The combination is not flagged in drug interaction databases, and the metabolic pathways do not overlap in a way that should raise atorvastatin blood levels.
• Atorvastatin should never be discontinued or dose-reduced in favor of NMN/NR. They serve completely different clinical purposes. Atorvastatin has strong cardiovascular mortality data from ASCOT-LLA (N=10,305) showing a 36% relative risk reduction in major cardiovascular events (PubMed PMID 12686036). NMN/NR have no cardiovascular outcomes data.
• Any new muscle pain while on this combination should be reported to the prescriber and evaluated as possible statin myopathy before assuming the supplement is to blame or is protective.
• Doses of NMN/NR above 1,000 mg/day have not been rigorously studied for safety in the context of statin co-therapy.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states that "clinicians should routinely ask patients about the use of dietary supplements that may affect statin tolerability or metabolism," a directive that directly applies here (AHA/ACC 2022 Cholesterol Guideline).

Special Populations

Older Adults

Adults over 60 are the demographic most likely to be on atorvastatin for primary or secondary cardiovascular prevention and simultaneously interested in NAD+ supplementation for longevity and metabolic support. This group also has lower baseline NAD+ levels, with whole-blood NAD+ declining by roughly 50 percent between ages 40 and 60 in cross-sectional data (PubMed PMID 28068221). They may be particularly motivated to supplement. Renal clearance of NAD+ catabolites may be reduced in this population, so starting at a lower NMN/NR dose (250 mg/day) and titrating upward is prudent.

People with Diabetes or Prediabetes

Atorvastatin carries an FDA label warning about a modest increase in HbA1c and fasting glucose. The Yoshino et al. Science trial mentioned above found that NMN 250 mg/day improved insulin sensitivity in postmenopausal women with prediabetes (PubMed PMID 34881074). These effects work in opposite directions on glycemic control, which could complicate interpretation of HbA1c trends. Clinicians managing both agents should keep this directional difference in mind rather than assuming the effects are negligible.

People with SLCO1B1 Variants

Patients known to carry the SLCO1B1 521T>C variant have roughly a 16.9-fold increased odds of statin-related myopathy at high atorvastatin doses per a CPIC guideline meta-analysis (PubMed PMID 22617227). These patients are already at elevated myopathy risk and require closer CK monitoring regardless of supplement use. Adding NMN/NR does not increase this genetic risk, but the monitoring bar should be higher.

The Bottom Line for Prescribers

The interaction between NMN/NR and atorvastatin is currently classified as theoretical and low severity. Atorvastatin's CYP3A4-dependent metabolism is not altered by NMN or NR based on available pharmacokinetic data. The pharmacodynamic story is more layered: both agents touch skeletal-muscle mitochondrial function, and future combination trials may reveal either additive benefit or unexpected interactions at higher doses.

Until randomized trial data specifically evaluating this combination are available, the most defensible clinical posture is to allow co-administration with standard statin monitoring (CK at baseline and 12 weeks), keep NMN/NR doses at or below 500 mg/day until higher-dose safety data mature, and document supplement use in the patient record so any future adverse event can be properly attributed.

Obtain a baseline CK before your patient starts NMN/NR if they are already on atorvastatin 40 mg or higher.